comparemela.com

Latest Breaking News On - கேன் பார்மா - Page 2 : comparemela.com

NervGen Pharma Corp : NervGen Engages Vorticom Inc to Provide Media Relations Services

NervGen Pharma Corp : NervGen Engages Vorticom Inc to Provide Media Relations Services
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

NervGen Pharma Corp : NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer s Disease Models

NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease Vancouver, British Columbia (Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"

(URGN) - Looking Into UroGen Pharma s Return On Capital Employed

(URGN) - Looking Into UroGen Pharma s Return On Capital Employed
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

NervGen Pharma Corp : NervGen Pharma Reports First Quarter 2021 Results

NervGen Pharma Corp.: NervGen Pharma Reports First Quarter 2021 Results NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. We achieved several key milestones in the first quarter of 2021 including receiving clearance from the FDA to proceed with our Phase 1 clinical trial for our lead compound, NVG-291, which has now commenced in Australia, stated Paul Brennan, NervGen s President & CEO. In addition, we established an Alzheimer s Disease Scientific Advisory Board comprised of world-class scientists and clinical researchers in Alzheimer s disease and have decided to initiate a multi-dose Alzheimer s disease patient cohort as a Phase 1b addition to our clinical program. We also received Orphan Designation for NVG-291 from the European Medicines Agenc

Head and Founder of DanCann Pharma Wins 2021 Business Worldwide Magazine CEO Award

Head and Founder of DanCann Pharma Wins 2021 Business Worldwide Magazine CEO Award News provided by Share this article Share this article LONDON, May 18, 2021 /PRNewswire/ The CEO and founder of DanCann Pharma A/S, Jeppe Krog Rasmussen, has been named in this year s Business Worldwide Magazine CEO Awards. He was the outright winner in his category - Most innovative CEO in Europe s Pharmaceuticals Industry. The awards seek to identify and honour the Most Respected C-level executives across the globe from a variety of different sectors. Unlike many other business awards that focus on the overall success of a company, here the spotlight is on the success of individuals who make the corporations tick– namely senior executives such as CEOs, Managing Directors, Directors and senior-level management. The intention is to give a worthy individual the recognition they deserve, whilst using their example to inspire other companies and business leaders to achieve similar success. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.